> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Solventum Lifts 2026 Earnings Outlook To $7.20–$7.30 As Advance Orders Reverse
- URL: https://www.bullished.co/solventum-lifts-2026-earnings-outlook-to-7-20-7-30-as-advance-orders-reverse-72d89f85/
- Published: 2026-11-06T15:21:50.000Z
- Updated: 2026-11-06T15:21:50.000Z
- Description: The healthcare supplier completed its business-system transitions, while wound care and software sales grew and dental sales fell.
- Author: Matteo Parrino
- Tags: Earnings, SOLV, Industry: Healthcare

[Solventum](https://www.bullished.co/tag/solv/), which makes medical and dental products and healthcare software, [raised its 2026](https://uk.finance.yahoo.com/news/solventum-solv-raises-guidance-q3-091715939.html?ref=bullished.co) adjusted earnings outlook to [$7.20–$7.30 per share](https://www.sec.gov/Archives/edgar/data/0001964738/000196473826000055/solv-20261105.htm?ref=bullished.co) from $7.10–$7.20 Thursday, despite lower third-quarter sales. Customers’ advance orders ahead of a business-management system switch reversed during the quarter, an expected effect the company said accounted for the sales decline excluding currency movements, acquisitions and divestitures.

## Advance Orders Distort The Quarter

Third-quarter revenue was [$1,949 million](https://www.prnewswire.com/news-releases/solventum-reports-third-quarter-2026-financial-results-302931277.html?ref=bullished.co) against $2,096 million a year earlier: down 7.0% as reported, or 2.8% excluding currency effects, acquisitions and divestitures. The reversal of orders placed in the second quarter reduced third-quarter growth on that latter basis by 6.30 percentage points.

Adjusted earnings reached [$1.45 per share](https://www.prnewswire.com/news-releases/solventum-reports-third-quarter-2026-financial-results-302931277.html?ref=bullished.co), versus $1.50 a year earlier. Adjusted operating margin was 19.9%, compared with 20.6%; management attributed that decline chiefly to the advance-order reversal. Both standard-accounting and adjusted gross margins improved, with product mix, portfolio changes and savings outweighing part of the pressure from inflation and tariffs.

The unaudited results showed a $12 million loss, or $0.07 per share, versus $1,266 million in profit a year earlier. The comparison includes a [$1,518 million gain](https://www.sec.gov/Archives/edgar/data/0001964738/000196473826000055/q32026-8kerexx991.htm?ref=bullished.co) from the September 2025 sale of purification and filtration operations. That gain and higher restructuring costs chiefly explained the deterioration in standard-accounting operating profitability, the company said.

SOLV shares jumped about 6% to $92.04 in Friday trading.

## Wound Care Grows, Dental Retreats

Solventum’s MedSurg business supplies wound treatments, infection-prevention products and surgical equipment. Its other segments sell dental and orthodontic products and software for healthcare documentation, coding and speech recognition.

Advanced wound care sales reached $528 million, versus $485 million a year earlier. Reported growth was 8.9%, while growth excluding currency effects and deals was 1.5%; the acquisition contribution included Acera, bought in December 2025\. Infection Prevention and Surgical Solutions sales fell to $683 million from $722 million, leaving MedSurg revenue at $1,211 million against $1,206 million.

Dental Solutions revenue declined to $317 million from $340 million. Health Information Systems moved the other way, with sales of $356 million versus $345 million and operating margin of 41.7% against 38.8%.

The FDA cleared the combined use of Restrata and V.A.C. Therapy, adding an integration milestone for Acera Surgical’s technology within Solventum’s wound-care portfolio.

## System Switches Done, Cash Outlook Unchanged

Solventum finished its business-management system transitions and exited approximately 90% of its service agreements with 3M. Bryan Hanson, Solventum’s chief executive officer, said, “With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to [accelerate sales growth](https://www.sec.gov/Archives/edgar/data/0001964738/000196473826000055/q32026-8kerexx991.htm?ref=bullished.co) and expand margins.”

Management expects full-year sales growth excluding currency effects, acquisitions and divestitures toward the high end of 2.5%–3.0%. For the first nine months, that measure grew 2.9%, even as reported sales fell 2.6% to $6,165 million. Adjusted earnings for that period were $5.48 per share, up from $4.53.

Third-quarter operating cash flow was $177 million, versus $75 million a year earlier. Free cash flow—operating cash remaining after capital spending—was $97 million, compared with negative $22 million. A tariff refund helped cash generation exceed management’s expectations.

Solventum retained its full-year free-cash-flow forecast of $200 million–$300 million; free cash flow for the first nine months remained negative $32 million.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Solventum Corp (SOLV)](https://www.sec.gov/Archives/edgar/data/0001964738/000196473826000055/solv-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit q32026-8kerexx991.htm — Solventum Corp 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001964738/000196473826000055/q32026-8kerexx991.htm?ref=bullished.co) — SEC EDGAR
- [Solventum (SOLV) Raises Guidance After Q3 Beat, Is The Stock Still Undervalued?](https://uk.finance.yahoo.com/news/solventum-solv-raises-guidance-q3-091715939.html?ref=bullished.co) — Yahoo Finance
- [Solventum Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/solventum-reports-third-quarter-2026-financial-results-302931277.html?ref=bullished.co) — prnewswire.com

### More on Solventum

- [Solventum Scraps A 100-Basis-Point Margin Hit From Its 3M Supply Deal](https://www.bullished.co/solventum-scraps-a-100-basis-point-margin-hit-from-its-3m-supply-deal-de5438db/)

[All Solventum (SOLV) coverage →](https://www.bullished.co/tag/solv/)